Last reviewed · How we verify
AMG 719
AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing.
AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing. Used for Acute myeloid leukemia (AML), FLT3-positive.
At a glance
| Generic name | AMG 719 |
|---|---|
| Sponsor | Amgen |
| Drug class | Bispecific T-cell engager (BiTE) |
| Target | CD3 and FLT3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
As a CD3 × FLT3 bispecific T-cell engager, AMG 719 bridges cytotoxic T lymphocytes to FLT3-expressing leukemic cells, promoting T-cell activation and tumor cell lysis. This approach leverages the patient's own immune system to target AML cells that express the FLT3 receptor, which is frequently present in acute myeloid leukemia.
Approved indications
- Acute myeloid leukemia (AML), FLT3-positive
Common side effects
- Cytokine release syndrome
- Infections
- Hematologic toxicity
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 719 CI brief — competitive landscape report
- AMG 719 updates RSS · CI watch RSS
- Amgen portfolio CI